Eagle Pharmaceuticals Reports Third Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 27c
November 9, 2021 6:51 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.56, $0.27 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $39.9 million versus the consensus estimate of $46.4 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... More